SCHEMBL10077965

SCHEMBL10077965

CN1CCC(Oc2ncc(F)cn2)CC1

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.43
LRRK2 Q5S007 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
ATR Q13535 2/20 0.38
KMT2A Q03164 1/20 0.38
AR P10275 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19764133 0.83 HRH3 (0.44) LRRK2HRH3SMN1; SMN2CHRM2CHRM4
SCHEMBL10057701 0.82 HRH3 (0.45) HRH3
SCHEMBL12929421 0.80 LRRK2 (0.48) LRRK2HRH3SMN1; SMN2CHRM2CHRM4
SCHEMBL20147962 0.79 TDO2 (0.61) TDO2HRH3SMN1; SMN2MAPT
SCHEMBL995078 0.77 HRH3 (0.45) LRRK2HRH3SMN1; SMN2CHRM2CHRM4
SCHEMBL19764135 0.76 MAPT (0.42) LRRK2HRH3MAPT
SCHEMBL940760 0.75 HRH1 (0.43) TDO2CHRM3
SCHEMBL20069132 0.75 HRH3 (0.46) LRRK2HRH3SMN1; SMN2CHRM4
SCHEMBL13873153 0.73 SMN1; SMN2 (0.47) SMN1; SMN2
SCHEMBL23405944 0.73 GSK3B (0.43) LRRK2HRH3SMN1; SMN2CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148404-B2 Modulators of CB1 receptors 7TM PHARMA A/S (DK) 2012-04-03 US disclosed
US-20100144701-A1 Modulators of CB1 Receptors 7TM PHARMA A/S (DK) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144701-A1 Modulators of CB1 Receptors CNR1, CNR2, GPR6 TDO2 2387/4885LRRK2 3118/4885HRH3 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.